XML 53 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Collaborative Arrangements and Licensing Agreements, Biogen (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
USD ($)
Target
Payment
Drug
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Drug
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 163,813 $ 117,747 $ 461,026 $ 262,165  
SPINRAZA Royalties [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue 70,502 56,653 130,212 97,734  
R&D Revenue [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 75,514 60,549 $ 304,640 162,944  
Biogen [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Number of additional drugs in clinical development to treat neurodegenerative diseases | Drug 6   6    
Cumulative payments received $ 2,200,000   $ 2,200,000    
Revenue 102,400 $ 78,000 186,600 $ 129,900  
Deferred revenue $ 540,800   $ 540,800   $ 580,900
Biogen [Member] | Revenue [Member] | Strategic Partner [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Concentration percentage 63.00% 66.00% 41.00% 50.00%  
Biogen [Member] | SPINRAZA Royalties [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 70,500 $ 56,700 $ 130,200 $ 97,700  
Biogen [Member] | R&D Revenue [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 31,900 21,300 56,400 $ 32,200  
2018 Strategic Neurology [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Upfront payment received   $ 1,000,000      
Number of milestone payments achieved | Payment 2        
Milestone payment received $ 7,500        
Number of new targets advanced | Target 2        
Next prospective milestone $ 7,500   7,500    
2018 Strategic Neurology [Member] | R&D Services [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Transaction price 582,000   582,000    
2012 Neurology [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Milestone payment received 7,500        
Next prospective milestone 10,000   10,000    
2012 Neurology [Member] | R&D Services for IONIS-MAPT [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Transaction price $ 25,500   $ 25,500